Search results
1 wrz 2021 · The following ESMO Clinical Practice Guideline has been recently updated with new treatment recommendations: Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.1.
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO ...
Lung cancer is the leading cause of cancer mortality...
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis ...
Small-cell lung cancer (SCLC) is the most aggressive form of...
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO ...
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still rising despite an ongoing small decline in the Western world. Global statistics estimate that 15% of lung cancers in men and 53% in women are not attributable to smoking, overall accounting for 25% [2].
14 kwi 2021 · Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy (RT), due to early treatment resistance, the 5-year overall survival (OS) is <10%. 1 The incidence of SCLC has decreased in recent decades, and with a prevalence of 1-5 ...
ESMO has Clinical Practice Guidelines on the following Lung and Chest Tumours: Early and locally advanced non-small-cell lung cancer, Metastatic non-small-cell lung cancer, Thymic epithelial tumours, Malignant pleural mesothelioma, Small-cell lung cancer.
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In 2012, lung cancer was the most frequently diagnosed cancer in males with an estimated 1.2 million incident cases worldwide. Among females, lung cancer was the leading
There are several methods to determine halitosis. Halitosis can be treated if its etiology can be detected rightly. The most important issue for treatment of halitosis is detection etiology or determination its source by detailed clinical examination.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment.
